TP53 and B-cell chronic lymphocytic leukemia: Although CLL patients with del(17p) were excluded from this trial, twelve ibrutinib-treated patients had mutated TP53. Their outcome following ibrutinib treatment was comparable to patients without TP53 mutations (5-year PFS rate 56% versus 73%, HR 0.87; 95%CI, 0.26-2.85).